13F-HR filed by Versant Venture Management, LLC
Versant Venture Management, LLC filed this 13F-HR for the quarter ended 2014-12-31, filed 2015-04-02, with 5 holding rows worth $104,586,174 by the sum of the rows.
- Accession
- 0001104659-15-025167
- Filer
- CIK 1560009
- Filed
- 2015-04-02
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2014
A holdings report, 5 entries on the cover page, a total value of $111,097,158 stated on the cover page (in dollars after the unit check, H1), rows summing to $104,586,174 with VALUE read as dollars, detected, 13F file number 028-16849. A later restatement replaced it, so the quarter does not use it. The resolved quarter.
The cover page states a total of $111,097,158, 6% more than the sum of the rows, $104,586,174. This page uses the sum of the rows.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CLOVIS ONCOLOGY INC | 189464100 | COM | 814,833 | $45,630,648 | dollars, detected | |
| FIVE PRIME THERAPEUTICS INC. | 33830X104 | Common Stock | 1,092,152 | $29,488,104 | dollars, detected | |
| ACHAOGEN INC | 004449104 | COM | 1,281,152 | $16,719,034 | dollars, detected | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 1,048,601 | $10,307,748 | dollars, detected | |
| KYTHERA BIOPHARMACEUTICALS I | 501570105 | COM | 70,376 | $2,440,640 | dollars, detected |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-15-025167 | this filing | 2015-04-02 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001104659-15-029151 | superseded | 2015-04-22 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001104659-15-029709 | base | 2015-04-23 | acceptance time not in the bulk data set |